SG11201502933UA - Anti-prokineticin receptor (prokr) antibodies and uses thereof - Google Patents

Anti-prokineticin receptor (prokr) antibodies and uses thereof

Info

Publication number
SG11201502933UA
SG11201502933UA SG11201502933UA SG11201502933UA SG11201502933UA SG 11201502933U A SG11201502933U A SG 11201502933UA SG 11201502933U A SG11201502933U A SG 11201502933UA SG 11201502933U A SG11201502933U A SG 11201502933UA SG 11201502933U A SG11201502933U A SG 11201502933UA
Authority
SG
Singapore
Prior art keywords
prokr
antibodies
prokineticin receptor
prokineticin
receptor
Prior art date
Application number
SG11201502933UA
Other languages
English (en)
Inventor
Lynn Macdonald
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201502933UA publication Critical patent/SG11201502933UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201502933UA 2012-11-13 2013-11-12 Anti-prokineticin receptor (prokr) antibodies and uses thereof SG11201502933UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725704P 2012-11-13 2012-11-13
US201361825112P 2013-05-20 2013-05-20
PCT/US2013/069673 WO2014078306A1 (en) 2012-11-13 2013-11-12 Anti-prokineticin receptor (prokr) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201502933UA true SG11201502933UA (en) 2015-05-28

Family

ID=49667597

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502933UA SG11201502933UA (en) 2012-11-13 2013-11-12 Anti-prokineticin receptor (prokr) antibodies and uses thereof

Country Status (18)

Country Link
US (3) US20140134189A1 (ja)
EP (1) EP2920211A1 (ja)
JP (1) JP2016502520A (ja)
KR (1) KR20150084007A (ja)
CN (1) CN104781280A (ja)
AU (1) AU2013345018A1 (ja)
BR (1) BR112015010691A2 (ja)
CA (1) CA2891327A1 (ja)
CL (1) CL2015001237A1 (ja)
CO (1) CO7400866A2 (ja)
EA (1) EA201590877A1 (ja)
HK (1) HK1210182A1 (ja)
IL (1) IL238629A0 (ja)
MX (1) MX2015005546A (ja)
PH (1) PH12015500903A1 (ja)
SG (1) SG11201502933UA (ja)
WO (1) WO2014078306A1 (ja)
ZA (1) ZA201502516B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207604B (zh) 2015-01-30 2021-10-26 学校法人埼玉医科大学 抗alk2抗体
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
JP2003516109A (ja) 1998-12-10 2003-05-13 シナプティック・ファーマスーティカル・コーポレーション 哺乳類の受容体（ｆｂ４１ａ）をコードするＤＮＡとその使用
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1242448A2 (en) 1999-11-17 2002-09-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
EP1302542B1 (en) 2000-07-18 2007-06-13 Takeda Pharmaceutical Company Limited Novel physiologically active peptide and use thereof
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
DE10229379A1 (de) 2002-06-26 2004-01-29 Schering Ag EG-VEGF Rezeptor Antagonisten
ATE419274T1 (de) 2002-10-25 2009-01-15 Mds Analytical Technologies Us Verfahren zur identifizierung von transmembranrezeptoragonisten mit reduzierter internalisierung
US7115560B2 (en) 2003-03-25 2006-10-03 The Regents Of The University Of California Methods for modulating gastric secretion using prokineticin receptor antagonists
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
EP1866290B1 (en) 2005-03-24 2013-05-01 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
ITRM20070182A1 (it) * 2007-04-03 2008-10-04 Univ Roma Antagonisti dei recettori delle prochineticine derivati di essi e loro uso
CA2686238C (en) 2007-05-15 2018-09-25 F. Hoffmann-La Roche Ag Metabotropic glutamate receptor 7(mglur7)-binding antibody
US20100286021A1 (en) 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
WO2010077976A2 (en) * 2008-12-17 2010-07-08 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
ITMI20111225A1 (it) * 2011-06-30 2012-12-31 Fond I R C C S Istituto Neur Ologico Carlo Uso di antagonisti non peptidici dei recettori per le prokineticine per la terapia di malattie autoimmuni o con componente autoimmune, o di malattie disimmuni o con componente disimmune

Also Published As

Publication number Publication date
US9951132B2 (en) 2018-04-24
US20140134189A1 (en) 2014-05-15
CA2891327A1 (en) 2014-05-22
AU2013345018A1 (en) 2015-05-14
KR20150084007A (ko) 2015-07-21
ZA201502516B (en) 2016-01-27
EA201590877A1 (ru) 2015-09-30
CL2015001237A1 (es) 2015-08-28
BR112015010691A2 (pt) 2017-08-22
HK1210182A1 (en) 2016-04-15
US20150266957A1 (en) 2015-09-24
US20180208656A1 (en) 2018-07-26
CO7400866A2 (es) 2015-09-30
MX2015005546A (es) 2015-08-05
IL238629A0 (en) 2015-06-30
PH12015500903A1 (en) 2015-07-13
WO2014078306A1 (en) 2014-05-22
EP2920211A1 (en) 2015-09-23
JP2016502520A (ja) 2016-01-28
CN104781280A (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
HK1205523A1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
EP2830660A4 (en) ANTI-SEMA4D ANTIBODIES AND EPITOPES
EP2861623A4 (en) NEW SPECIFIC CLEC14A ANTIBODY AND USES THEREOF
PL2831117T3 (pl) Przeciwciała anty-TLR4 i ich zastosowania
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HRP20180664T1 (hr) Nova protutijela protiv receptora fc-gama iib i njihova upotreba
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)
GB201208372D0 (en) Antibodies and uses thereof
GB201209584D0 (en) Modified antibodies